How does testosterone cypionate bind to the androgen receptor at a molecular level?

After ester hydrolysis releases free testosterone, the hormone diffuses into target cells and binds the cytosolic androgen receptor (AR), displacing chaperone proteins and inducing a conformational change. The activated AR dimerises and translocates to the nucleus, where it binds androgen response elements (AREs) in DNA, initiating transcription of genes governing muscle protein synthesis, red blood cell production, and bone mineralisation.

Why is testosterone classified as a DHT-derivative precursor and what does that mean for receptor activity?

Testosterone is the direct enzymatic precursor to dihydrotestosterone (DHT) via 5α-reductase activity. DHT binds the androgen receptor with two to three times the affinity of testosterone and forms a more stable receptor complex. This means tissues rich in 5α-reductase — such as the prostate, scalp, and skin — experience amplified androgenic signalling relative to tissues where testosterone acts directly, explaining tissue-selective androgenic effects.

Does the cypionate ester itself have any androgen receptor activity?

No — the cypionate ester has zero intrinsic androgen receptor affinity. Its sole function is to increase the lipophilicity of testosterone for intramuscular depot formation, slowing systemic absorption and extending the release window. Esterase enzymes cleave the ester bond in vivo, liberating unmodified testosterone, which is the active species responsible for all AR-mediated pharmacological effects.

What is the advantage of single-dose 1ml ampoules over multi-dose vials for maintaining dose precision?

Single-dose glass ampoules eliminate the risk of microbial contamination from repeated needle puncture and prevent the volume-measurement drift that can occur as multi-dose vials are progressively depleted. Each ampoule contains exactly one dose, sealed at manufacture — preserving solution sterility and concentration integrity from production to injection, which is directly relevant to consistent serum testosterone levels and predictable receptor saturation.

How should Elbrus Testosterone Cypionate 10x1ml ampoules be stored to maintain stability?

Store ampoules at controlled room temperature between 15°C and 25°C (59°F–77°F), away from direct light and humidity. Do not refrigerate oil-based injectable solutions, as cold temperatures can increase viscosity and cause precipitation of the dissolved compound. Inspect each ampoule visually before use; discard if particulate matter, discolouration, or glass integrity compromise is observed. Use each ampoule immediately after opening — single-dose units must not be stored after the seal is broken. (2) angle_used

Optimal Dosage

Elbrus Pharmaceuticals

Testosterone Cypionate 250mg/ml 10x1ml Ampullen by Elbrus Pharmaceuticals

Name: Testosterone Cypionate 250mg/ml 10x1ml Ampoules by Elbrus Pharmaceuticals
Brand: Elbrus Pharmaceuticals
SKU: INJ-TCYP-ELB-250-007
Price: 40.00 EUR
Availability: InStock

Elbrus Pharmaceuticals Testosterone Cypionate 250mg/ml is a long-acting injectable androgen formulated at 250mg/ml across 10 individual single-dose glass ampoules, engineered around the full androgen receptor genomic pathway — from cytosolic AR binding through nuclear ARE-driven transcription of anabolic target genes. Each 1ml ampoule delivers a sealed, contamination-free 250mg dose of Testosterone Cypionate, a compound that undergoes both 5α-reductase conversion to DHT and aromatase-mediated oestradiol production, activating androgenic and estrogenic signalling in parallel. Finished-batch quality is confirmed through HPLC potency quantification and LAL endotoxin testing under GMP-certified aseptic fill-finish conditions before any ampoule is released.

€40.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Activates the full androgen receptor genomic pathway, including ARE-driven transcription of muscle and bone anabolic genes
Provides complete 5α-reductase substrate availability for physiological DHT synthesis in target tissues
Delivers 250mg per ampoule — a concentration matched to both 125mg and 250mg receptor-saturation dosing protocols without volume waste
Single-use glass ampoules preserve sterility and solution integrity from manufacture to point of injection
HPLC-verified active pharmaceutical ingredient content ensures the labelled 250mg/ml concentration is what reaches the androgen receptor
LAL endotoxin testing on finished batches reduces pyrogenic risk associated with parenteral androgen administration
Long cypionate ester supports stable inter-injection serum levels, sustaining AR occupancy across the dosing interval

Phase	Dosage	Note
Receptor Priming / Low-Dose Entry	125mg (0.5ml) every 7 days	Establishes initial AR saturation without rapid accumulation; suitable for first-cycle users or those re-sensitising after a break
Maintenance / Therapeutic Range	250mg (1ml) every 7 days	Single ampoule per injection; supports sustained supra-physiological testosterone for AR-mediated anabolic signalling
Advanced Receptor Loading	375–500mg (1.5–2ml across two ampoules) per week, split into two injections	Approaches receptor saturation ceiling; estrogenic and androgenic monitoring becomes critical at this range
PCT Transition	Taper to 125mg in final week, then discontinue	Allows serum levels to decline before initiating SERMs; HPTA recovery timeline guided by post-cycle bloodwork

Key takeaways

Understand that AR genomic signalling drives all primary anabolic effects of this compound.
Recognise DHT conversion as an inherent part of testosterone's receptor-level pharmacology.
Choose single-dose ampoules to eliminate contamination risk with each injection.
Confirm HPLC-validated concentration before calculating androgen receptor saturation doses.
Monitor 5α-reductase-sensitive tissues when running sustained testosterone cypionate protocols.

How Testosterone Cypionate Engages the Androgen Receptor

Testosterone Cypionate is a synthetic testosterone ester whose pharmacological identity is defined by covalent binding of liberated free testosterone to the cytosolic androgen receptor (AR), a member of the nuclear receptor superfamily encoded by the AR gene on the X chromosome. Once testosterone crosses the cell membrane and displaces heat-shock proteins from the AR, the ligand-receptor complex undergoes conformational change, dimerises, and translocates to the nucleus — directly binding androgen response elements (AREs) in target gene promoters. This genomic signalling pathway is the primary mechanism behind testosterone's anabolic effects on skeletal muscle, bone mineral density, and haematopoiesis. Compared to synthetic anabolic steroids designed to resist 5α-reduction, testosterone cypionate retains full substrate availability for 5α-reductase — meaning DHT generation in androgen-sensitive tissues (scalp, prostate, skin) is part of its endogenous pharmacology, not an artefact.

AR Binding Affinity, DHT Conversion, and Downstream Potency

Testosterone itself carries a relative binding affinity (RBA) for the androgen receptor of approximately 100% in standardised assay models (reference: Saartok et al., 1984, Endocrinology), establishing it as the physiological baseline against which synthetic androgens are measured. DHT — produced from testosterone via 5α-reductase type I and type II isoforms — binds the AR with roughly two to three times the affinity of testosterone, producing more stable receptor complexes and slower dissociation rates in target tissues. The cypionate ester does not itself interact with the AR; it functions exclusively as a solubility and depot-release vehicle, with esterase activity liberating free testosterone at the injection site and in circulation. This substrate-receptor architecture means testosterone cypionate activates the full physiological androgen axis — AR-genomic, non-genomic rapid signalling, and intracrine DHT production — rather than a truncated synthetic analogue pathway.

Receptor-Level Rationale for Dosing Elbrus 250mg/ml

Optimal androgen receptor saturation requires sustained serum testosterone levels within the supra-physiological or therapeutic range, which is why injection frequency and concentration both matter at the receptor level. Elbrus Pharmaceuticals formats this compound at 250mg/ml in single-use 1ml ampoules, giving practitioners discrete, contamination-free dosing units directly calibrated to common 125mg (0.5ml) and 250mg (1ml) receptor-saturation protocols. The single-dose ampoule format eliminates multi-puncture degradation risk and supports dose accuracy — both relevant to maintaining the stable serum testosterone concentrations that maximise AR occupancy over the injection interval.

Usage

Confirm the ampoule label states Testosterone Cypionate 250mg/ml and check the glass integrity and solution clarity before proceeding — any cloudiness or particulate matter is grounds for discarding the unit.
Calculate your target dose based on your protocol phase; at 250mg/ml, 0.5ml delivers 125mg and 1.0ml delivers the full 250mg single-dose ampoule content.
Snap open the ampoule at the scored neck using a sterile gauze pad, withdrawing the full volume with a draw needle of appropriate gauge for oil-based solutions.
Switch to an injection needle appropriate for your chosen site — typically 23–25 gauge for intramuscular administration into the gluteus medius or vastus lateralis.
Clean the injection site with an alcohol swab and allow it to air-dry fully before inserting the needle; aspirate briefly to confirm no intravascular placement, then administer the dose slowly over 10–15 seconds.
Rotate injection sites across successive ampoules to prevent localised tissue fibrosis; discard the opened single-dose ampoule, used needles, and draw equipment in a puncture-resistant sharps container immediately after use.

Warnings

Contraindications: Contraindicated in individuals with known or suspected androgen-sensitive malignancies, including prostate carcinoma and male breast cancer.

Not indicated for use in women of childbearing potential due to virilisation risk mediated by androgen receptor activation in female tissues.

Contraindicated in individuals with hypercalcaemia or pre-existing polycythaemia where erythropoietic AR stimulation would worsen haematological parameters.

Side_Effects: Androgenic: accelerated scalp hair thinning in 5α-reductase-sensitive individuals, acne, increased sebum production via AR activation in sebaceous glands.

Estrogenic: aromatase-mediated conversion to oestradiol may produce gynaecomastia, water retention, and elevated blood pressure without concurrent AI management.

Haematological: testosterone-driven erythropoiesis can raise red blood cell mass and haematocrit, increasing blood viscosity and cardiovascular strain.

Endocrine: exogenous testosterone suppresses LH and FSH secretion through hypothalamic-pituitary negative feedback, leading to testicular atrophy and impaired spermatogenesis during administration.

Monitoring: Serum total testosterone and free testosterone: measured at trough (immediately before next injection) to verify steady-state levels within the target range.

Full blood count including haematocrit: monitored to detect erythrocytosis — therapeutic phlebotomy or dose reduction may be required if levels approach clinically significant thresholds.

Lipid panel and liver function: assessed at baseline and periodically during administration; exogenous androgens may adversely shift HDL/LDL ratios.

Prostate-specific antigen (PSA): baseline and periodic screening in males over 40 or those with elevated androgenic risk profile.

PCT: Initiate a structured post-cycle therapy protocol after confirming serum testosterone has declined sufficiently following the last injection.

SERM therapy (tamoxifen or clomiphene) restores endogenous HPT axis function by competitively blocking oestrogen-mediated suppression at the hypothalamic and pituitary level.

Bloodwork confirmation of recovering LH, FSH, and endogenous testosterone levels guides the duration of PCT — discontinuation based on laboratory data rather than fixed calendar duration.

Frequently asked questions

How does testosterone cypionate bind to the androgen receptor at a molecular level?: After ester hydrolysis releases free testosterone, the hormone diffuses into target cells and binds the cytosolic androgen receptor (AR), displacing chaperone proteins and inducing a conformational change. The activated AR dimerises and translocates to the nucleus, where it binds androgen response elements (AREs) in DNA, initiating transcription of genes governing muscle protein synthesis, red blood cell production, and bone mineralisation.
Why is testosterone classified as a DHT-derivative precursor and what does that mean for receptor activity?: Testosterone is the direct enzymatic precursor to dihydrotestosterone (DHT) via 5α-reductase activity. DHT binds the androgen receptor with two to three times the affinity of testosterone and forms a more stable receptor complex. This means tissues rich in 5α-reductase — such as the prostate, scalp, and skin — experience amplified androgenic signalling relative to tissues where testosterone acts directly, explaining tissue-selective androgenic effects.
Does the cypionate ester itself have any androgen receptor activity?: No — the cypionate ester has zero intrinsic androgen receptor affinity. Its sole function is to increase the lipophilicity of testosterone for intramuscular depot formation, slowing systemic absorption and extending the release window. Esterase enzymes cleave the ester bond in vivo, liberating unmodified testosterone, which is the active species responsible for all AR-mediated pharmacological effects.
What is the advantage of single-dose 1ml ampoules over multi-dose vials for maintaining dose precision?: Single-dose glass ampoules eliminate the risk of microbial contamination from repeated needle puncture and prevent the volume-measurement drift that can occur as multi-dose vials are progressively depleted. Each ampoule contains exactly one dose, sealed at manufacture — preserving solution sterility and concentration integrity from production to injection, which is directly relevant to consistent serum testosterone levels and predictable receptor saturation.
How should Elbrus Testosterone Cypionate 10x1ml ampoules be stored to maintain stability?: Store ampoules at controlled room temperature between 15°C and 25°C (59°F–77°F), away from direct light and humidity. Do not refrigerate oil-based injectable solutions, as cold temperatures can increase viscosity and cause precipitation of the dissolved compound. Inspect each ampoule visually before use; discard if particulate matter, discolouration, or glass integrity compromise is observed. Use each ampoule immediately after opening — single-dose units must not be stored after the seal is broken. (2) angle_used

Manufacturer

Elbrus Pharmaceuticals positions its formulation development capability as the differentiating axis of its product identity — not catalogue breadth, but depth of process engineering behind each molecule it elects to manufacture. For Testosterone Cypionate 250mg/ml, the formulation development focus is on solvent-excipient balance: achieving a solution viscosity that remains injectable through clinically practical needle gauges while maintaining API stability across the declared shelf life. The company applies controlled stress-testing protocols to candidate formulations — accelerated thermal and photostability studies aligned with ICH Q1 guidance — to validate that the excipient system does not degrade the ester linkage or introduce impurity profiles beyond accepted pharmacopoeial limits. This formulation-first discipline means the 250mg/ml concentration in single-dose ampoules is not a default specification copied from convention but an output of stability data confirming that concentration, solvent ratio, and ampoule fill volume together meet release specifications. Elbrus treats formulation innovation not as the addition of novel excipients but as the rigorous optimisation of proven parenteral systems — an approach that prioritises reproducibility and regulatory defensibility over novelty for its own sake.

Product details

Brand	Elbrus Pharmaceuticals
Active ingredient	testosterone cypionate
Also known as	Testosterone Cypionate, Test C, Depo-Testosteronee, Testosteronee Cypionatee, Elbrus Pharmaceuticals Testosterone Cypionate
Strength	250 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-TCYP-ELB-250-007

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Cipandrol 200mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Cipandrol 200mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Cipandrol is a pharmaceutical-grade injectable testosterone preparation built around Testosterone Cypionate at 200 mg/ml — a compound whose origins trace back to American clinical research of the 1950s, when chemists at Upjohn first attached the cypionate ester to extend testosterone's therapeutic window. Presented in individual glass ampoules (10 × 1 ml), each unit delivers a precise, single-use dose free from the cross-contamination risk inherent in repeatedly punctured multi-dose vials. Sterility and potency are verified through independent HPLC quantification and LAL endotoxin screening conducted at Balkan Pharmaceuticals' GMP-certified Chișinău facility.

€38.00

High Concentration

Cypo-Testosterone 200mg/ml 10ml Vial by Beligas Pharmaceuticals

Cypo-Testosterone by Beligas Pharmaceuticals is a single-ingredient injectable androgen — Testosterone Cypionate at 200 mg per millilitre in a 10 ml multi-dose vial — engineered specifically to slot into structured, periodised cycle frameworks. At this concentration, each 1 ml draw delivers a precise 200 mg dose, giving cycle planners clean arithmetic when calculating weekly volume across bulking, maintenance, or recomposition phases. Quality assurance is enforced at every stage: HPLC-verified potency, LAL endotoxin testing, and GMP-certified filling conditions underpin every vial released under the Beligas label.

€38.00

Testacyp-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Testacyp-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testacyp-250 is an oil-based injectable testosterone ester in which Testosterone Cypionate at 250 mg/ml is engineered around its extended pharmacokinetic profile — delivering a clinically measurable half-life of approximately 8 days that sustains androgen receptor saturation between injections. Each 1 ml single-dose ampoule provides precise, pre-measured delivery in a hermetically sealed format that eliminates multi-use contamination risk. Quality assurance at BM Pharmaceuticals is built into every production stage: HPLC potency verification, LAL endotoxin screening, and GMP-certified fill-finish operations underpin every released batch.

€38.00

Brand Quality

CypioTrex 350mg/ml 10ml Vial by Concentrex Labs

CypioTrex is a high-concentration testosterone cypionate injectable — 350 mg/ml in a 10 ml multi-dose vial — engineered specifically for athletes running structured cruise-and-blast protocols that require distinct, clearly separated androgenic phases. At 350 mg/ml, each millilitre delivers 75% more active compound than standard 200 mg/ml preparations, reducing injection volume while maintaining full dosing flexibility across both the high-output blast window and the lower-dose cruise interval. Every batch is released only after passing in-house HPLC potency verification and LAL endotoxin screening, with GMP-aligned documentation supporting each production stage.

€38.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00